Last quarter (Q4 2023), Artelo Biosciences's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Artelo Biosciences's net income was $-3.07M. See Artelo Biosciences’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Aug 21	Aug 20	Aug 19
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 9.93M	$ 9.93M	$ 10.29M	$ 7.44M	$ 4.69M	$ 3.21M
Operating Income	$ -9.93M	$ -9.93M	$ -10.29M	$ -7.44M	$ -4.69M	$ -3.21M
Net Non Operating Interest Income Expense	$ 124.00K	-	$ 204.00K	$ 4.00K	$ 1.00K	-
Other Income Expense	$ -488.00K	$ -641.00K	$ 24.00K	-	$ 30.00K	$ 1.04M
Pretax Income	$ -9.32M	$ -9.29M	$ -10.11M	$ -7.44M	$ -4.66M	$ -2.17M
Tax Provision	$ 1.21M	$ 1.21M	-	-	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -9.32M	$ -9.29M	$ -10.11M	$ -7.44M	$ -4.66M	$ -2.17M
Basic EPS	-	-	-	-	$ -1.26	$ -1.00
Diluted EPS	-	-	-	$ -6.00	$ -1.26	$ -1.46
Basic Average Shares	-	-	-	$ 1.25B	$ 3.71M	$ 2.17M
Diluted Average Shares	-	-	-	$ 1.25B	$ 3.71M	$ 2.17M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 9.93M	$ 9.93M	$ 10.29M	$ 7.44M	$ 4.69M	$ 3.21M
Net Income From Continuing And Discontinued Operation	$ -9.29M	$ -9.29M	$ -10.08M	$ -7.44M	$ -4.66M	$ -2.17M
Normalized Income	$ -5.63M	$ -7.34M	-	-	$ -4.68M	$ -3.18M
Interest Expense	-	-	-	-	-	-
EBIT	$ -9.32M	$ -9.29M	$ -10.10M	$ -7.44M	$ -4.69M	$ -3.21M
EBITDA	$ -9.32M	$ -9.29M	$ -10.10M	$ -7.44M	$ -4.69M	$ -3.21M

Currency in USD

Artelo Biosciences Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing